[Anticoagulation for atrial fibrillation : the future has begun]

Area of Science:

• Cardiology
• Pharmacology
• Health Economics

Context:

• Atrial fibrillation patient management guidelines are evolving, with lower thresholds for anticoagulation therapy initiation based on the CHAD(2)DS(2)-VASc score.
• Vitamin K antagonists (VKAs) remain the standard anticoagulation, but pose challenges including bleeding risk and the necessity for regular coagulation monitoring.
• Many patients requiring anticoagulation are undertreated due to VKA-associated complications.

Purpose:

• To review the development and potential benefits of newer anticoagulant agents (apixaban, rivaroxaban, dabigatran) for atrial fibrillation.
• To highlight the advantages of novel anticoagulants, such as the absence of routine coagulation monitoring and reduced bleeding risk.
• To emphasize the need for socioeconomic evaluations comparing novel anticoagulants with VKAs.

Summary:

• Newer oral anticoagulants like apixaban, rivaroxaban, and dabigatran have been developed to overcome the limitations of vitamin K antagonists in atrial fibrillation.
• These novel agents eliminate the need for routine blood tests and may reduce bleeding complications, improving patient adherence and outcomes.
• Dabigatran is already approved for thromboembolism prophylaxis in atrial fibrillation patients.

Impact:

• The introduction of novel anticoagulants may improve treatment rates and patient adherence for atrial fibrillation.
• Further socioeconomic studies are crucial to determine if the clinical benefits and cost savings associated with new anticoagulants justify their higher acquisition costs compared to VKAs.
• Optimizing anticoagulation therapy in atrial fibrillation has significant implications for preventing stroke and systemic embolism.